Orbimed Capital GP Viii LLC

Orbimed Advisors LLC (Director) sold 85,918 shares of SION at $44.86 on 2026-07-07 under 10b5-1 plan; sixth SION transaction in three months.

Orbimed Advisors LLC sold 85,918 shares for $3,854,281.48 on 2026-07-07 as part of a pre-arranged 10b5-1 trading plan, reducing holdings from 2,555,877 shares to 2,469,959 shares. This sale is the most recent in a sequence: the insider has executed five prior sales at SION since 2026-04-18, with measured 30-day returns of -11.9%, -20.7%, -20.7%, -26.4%, and trailing the most recent sale on 2026-06-30 where outcome is not yet measurable. The broader cross-ticker track record shows 15 prior sells with an average 30-day return of -14.3%, while the company reports a net loss of $26,779,000.00 and a market cap of $2,029,055,830.20. The current stock price of $44.94 is -7.2% from the 52-week high of $48.44, despite the stock being up +33.4% over the past 30 days and +18.6% over 90 days. The scheduled nature of this transaction under the 10b5-1 plan removes discretion from the timing, but the frequency and magnitude of sales within a three-month window against a loss-making company warrant investor scrutiny of the company's operational and financial trajectory.

Orbimed Advisors LLC (Director) sold 115,844 shares of SION at $45.50 on 2026-06-30 under 10b5-1 plan; stock now at $43.99

Orbimed Advisors LLC executed a scheduled sale of 115,844 shares at $45.50 as part of a pre-arranged 10b5-1 trading plan. Post-transaction holdings remain substantial at 2,555,877 shares. The transaction occurred on 2026-06-30; current price of $43.99 is -9.2% from the 52-week high of $48.44. Notably, this director has recently executed four other sales at SION on 2026-05-11, 2026-05-08, 2026-05-07, and 2026-04-18—each resulting in 30-day post-sale declines of -26.4%, -20.7%, -20.7%, and -11.9% respectively. The underlying company is unprofitable, reporting net income of $-26,779,000.00 for its most recent full fiscal year. Given the scheduled nature of this sale under a 10b5-1 plan and the recent pattern of post-sale declines in the same ticker, investors should monitor whether this reflects pre-planned capital allocation or a directional shift in the insider's assessment.

Director Orbimed Advisors Llc sells ~293k shares (~$13.4M) over three days as stock trades near its 52-week high.

Orbimed Advisors, a director at Sionna Therapeutics, disposed of roughly 293,000 shares across three trading days in early May, representing approximately 10% of their total holding and netting over $13 million. The timing is notable: the stock has rallied significantly over the prior quarter and trades near its 52-week high, a position where insiders often choose to lighten exposure. However, this director's own historical record at this company shows mixed timing on prior sales—about half of their previous exits saw the stock rise afterward (poorly timed exits), while the other half preceded stock declines (well-timed exits). The company itself remains unprofitable with substantial net losses and negative earnings, so this sale comes against the backdrop of fundamental weakness. Orbimed's filing history shows a clear pattern: 144 prior open-market sales across all holdings over the 36-month window, with this transaction representing the 145th-147th sale. The volume and frequency of sales relative to zero open-market purchases in the same period suggests this is a holder managing a large position, not an insider with accumulated operational conviction in the company.

OrbiMed Advisors acquires 597,729 shares of Traws Pharma at $1.67 as losses widen; stock down 61.3% YTD

OrbiMed Advisors, a 10% shareholder, purchased 597,729 shares at $1.67 on 2026-04-16, nearly doubling its stake from 605,521 to 1,203,250 shares. The transaction occurred amid a sharp deterioration: Traws reported a net loss of $-3.0M against revenue of $2.7M, and the stock has declined 61.3% from its 52-week high of $3.13. Notably, OrbiMed's cross-ticker buy track record shows 6 prior purchases with an average 90-day return of +360.7% and a 100% win rate, though this represents historical performance across multiple holdings, not predictive evidence of outcomes at Traws specifically. The purchase price of $1.67 now trades 27% below the transaction price at a current price of $1.21, reflecting continued negative momentum (30-day decline of -31.2%) since the acquisition.

ORBIMED ADVISORS LLC sells 55,345 shares of SION for $2,472,342.92 via scheduled 10b5-1 plan

ORBIMED ADVISORS LLC sold 2 separate tranches totaling 55,345 shares at a blended average price of $44.67 on April 17–18, 2026, for a combined $2,472,342.92. This sale reduced the director's holdings from 3,020,119 shares to 2,964,774 shares, a net decrease of 1.8%. The transaction was executed under a pre-arranged 10b5-1 trading plan, indicating the sales were scheduled rather than discretionary. Since the trades are programmatic, no timing-based inference about insider conviction is warranted; the filing reflects a pre-determined execution schedule rather than a spontaneous response to market conditions.

OrbiMed Advisors LLC sold 510,583 shares at $44.51–$45.34 (avg $44.94) for $22,945,043.50 via scheduled 10b5-1 plan

OrbiMed Advisors LLC, a director of Sionna Therapeutics, executed 3 separate sales totaling 510,583 shares for $22,945,043.50 on 2026-04-14 through 2026-04-16, reducing holdings from 3,530,702 shares to 3,020,119 shares. This disposition represents a 14.5% reduction in the director's position and was conducted pursuant to a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary. With OrbiMed maintaining 3.02M shares post-transaction, the director retains a substantial stake in the company, though the magnitude of this scheduled liquidation ($22.9M across three days) warrants attention to any related disclosures about the plan's terms, duration, or OrbiMed's broader investment thesis.

Director ORBiMed Advisors LLC sold 30,953 shares at $44.57–$44.58 for $1,379,865.84; retains 3,530,702 shares

ORBiMed Advisors LLC, a director at Sionna Therapeutics, executed 2 separate sales totaling 30,953 shares for $1,379,865.84 on February 2–3, 2026, reducing holdings from 3,561,655 to 3,530,702 shares (a -0.9% reduction). The stock is now trading at $41.32, down 7.1% from the 52-week high of $44.48, while the broader 90-day trend shows +20.1% appreciation. ORBiMed's prior sales at SION have not exhibited well-timed 90-day outcomes (0 of 4 measurable), and his cross-ticker sell history shows a 66.67% well-timed rate; the company's net income of $-20,278,000.00 and 3.53M-share post-transaction holdings reflect its pre-revenue/early-stage biotech profile. This sale occurs near the stock's 52-week highs and follows a cluster of four sales in late November–December 2025, warranting tracking of whether this reflects a broader position reduction at this holder level.

Director ORBIMED ADVISORS LLC sold 33,356 shares of SION at $44.55 on 2025-12-24, reducing holdings from 3.60M to 3.56M shares.

ORBIMED ADVISORS LLC sold 33,356 shares (33.4K shares) at $44.55, representing a 0.9% reduction from pre-transaction holdings of 3,595,011 shares (3.60M shares). The sale occurred at a price near the 52-week high of $44.38, within 3.5% of peak valuations despite a current price of $42.81. Contextually, the insider's cross-ticker track record shows a 70.00% well-timed sell rate across 14 prior open-market sales (higher returns after the sale indicate poor timing; negative 90d average of +0.7% suggests marginal execution), though this same-ticker history at SION is nascent—three prior consecutive sales on 2025-11-24, 2025-11-25, and 2025-11-26 each showed modest declines over 30 days but lack measurable 90-day outcomes. The company faces structural headwinds: net income of $-20,278,000.00 ($-20.3M) paired with a $1.9B market cap signals an early-stage biotech without near-term profitability.

ORBiMed Advisors LLC sold 108,073 shares at blended avg $44.55 (3 sales, $4.8M) via 10b5-1 plan

ORBiMed Advisors LLC, a director, executed 3 separate sales totaling 108,073 shares for $4,814,204.82 across 2025-11-24 to 2025-11-26 at prices ranging from $44.49 to $44.60. The transaction reduced the director's holdings from 3,704,959 shares to 3,596,886 shares, a net reduction of 2.9% of pre-transaction holdings. This sale was conducted under a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than discretionary. The modest scale relative to the 3.60M share post-transaction position and the scheduled nature of the plan limit the signaling value of this specific filing.